Lachman has been providing
both onsite and remote
support to our clients
for many years.

Review Support Offerings
The Lachman Difference

The most efficient services.
The most qualified professionals.

Since 1978, Lachman Consultants’ multidisciplinary team of highly experienced FDA consultants and industry experts has offered compliance, regulatory affairs, and science & technology services to clients around the world.

Learn More About Us

Stay in the know

Sign up today for the Lachman Consultants blog.

Get the latest news on industry compliance, regulatory affairs, technical services, and a whole lot more.

    Lachman Practice Groups

    Three Practices
    Executing One Vision

    Lachman Consultants maintains three practice groups: Compliance, Regulatory Affairs, and Science and Technology. Each practice offers industry-leading experience and expertise in its area of focus.

    Lachman OnCall Logo

    Get the answers and guidance to your most pressing questions faster than ever before.

    Now you can speak to one of our Subject Matter Experts and get the answers you need quickly on the many pressing issues arising in the life science areas that Lachman Consultants serves on a day to day basis. Whether it’s something you need to know about compliance, or a complex scientific or technical issue, Lachman OnCall™️ can provide you the timely information you require as needs arise and unforeseen questions occur.

    Learn More About Lachman OnCall

    OnCall Image

    Recent Posts

    The Lachman Consultants Blog

    The latest on industry compliance, regulatory affairs, technical services, and a whole lot more.

    Data Integrity Series: Episode 4

    Episode #4 of our six-part Data Integrity video series focuses on Syst...
    Read More

    UFAs Set to Pass; What is a Sponsor to Do?

    All indications seem to be that all the User Fee reauthorizations (lov...
    Read More

    Sally Choe OGD Director Leaving!

    According to Zachary Brennan’s story on Endpoints (here),  Sally Ch...
    Read More

    Feedback from Industry on July 2022 Guidance Regarding TE Ratings for 505(b)(2) Products

    I read a great article by Joanne S. Egolvitch in the RAPS Regulatory N...
    Read More

    September 2022 Peek at Approval Actions

    Based on a strong start to the month, the OGD has issued forty approva...
    Read More

    AAM 2022 Report on Generic and Biosim Savings for 2021

    It’s no surprise that the use of generic drugs saves consumers and h...
    Read More
    Contact Us Today